Publications, Pharmaceutical

Using Bioequivalence and Particle Size Distribution to Develop OINDPs

The complexity of demonstrating bioequivalence in complex locally acting orally inhaled and nasal drug products is a barrier to the successful commercialization of generics.

This paper details a study to investigate the performance of a population bioequivalence (PBE) test based on particle size distribution measurements generated by morphologically directed Raman spectroscopy. Simulations of PBE trials were conducted across a range of median particle size and span values. Trial optimization strategies are presented based on the observed data and the general applicability of the approach is underlined. Appropriate trial design can help generic developers to avoid underpowered studies when using complex in vitro techniques to demonstrate bioequivalence.

Download Publication
6 Oct 2020

Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery

Find Out More

This Might Also Be of Interest

3 Jul 2023

Nasal Spray Orientation & Sumatriptan Exposure using PK Modelling

Publications, Pharmaceutical, Brand Differentiation, Market Insights, Product Solutions, Drug Delivery Innovations

Read More
3 Jul 2023

Leachables Assessment: New pMDI with Low-GWP Propellants

Publications, Pharmaceutical, Sustainability, Drug Delivery Innovations, Brand Differentiation, Market Insights, Product Solutions

Read More
3 Jul 2023

Intranasal Vaccination: Rationale, Progress and Challenges

Publications, Pharmaceutical, Drug Delivery Innovations, Brand Differentiation, Market Insights, Product Solutions

Read More
3 Jul 2023

Performance of Low-GWP Propellants in pMDIs: Filling and Dose Evaluation

Publications, Pharmaceutical, Market Insights, Product Solutions, Sustainability, Drug Delivery Innovations

Read More
1 … 6 7 8 9 10 … 36

Request Access

Close

Requesting access to Using Bioequivalence and Particle Size Distribution to Develop OINDPs.

  • This field is hidden when viewing the form
  • This field is hidden when viewing the form
  • This field is hidden when viewing the form
  • This field is hidden when viewing the form
  • This field is hidden when viewing the form
  • This field is hidden when viewing the form
  • This field is hidden when viewing the form
  • This field is for validation purposes and should be left unchanged.

How Can We Help?

Back To Top